Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Győrffy B[au]:

Search results

Items: 1 to 50 of 248

1.

Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.

Merino VF, Cho S, Nguyen N, Sadik H, Narayan A, Talbot C Jr, Cope L, Zhou XC, Zhang Z, Győrffy B, Sukumar S.

Breast Cancer Res. 2018 Nov 28;20(1):145. doi: 10.1186/s13058-018-1068-x.

2.

Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene.

Noblejas-López MDM, Morcillo-García S, Nieto-Jiménez C, Nuncia-Cantarero M, Győrffy B, Galan-Moya EM, Pandiella A, Ocaña A.

PLoS One. 2018 Nov 28;13(11):e0207776. doi: 10.1371/journal.pone.0207776. eCollection 2018.

3.

EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer.

Atkinson CJ, Kawamata F, Liu C, Ham S, Győrffy B, Munn AL, Wei MQ, Möller A, Whitehall V, Wiegmans AP.

Mol Oncol. 2018 Nov 26. doi: 10.1002/1878-0261.12411. [Epub ahead of print]

4.

Dynamin impacts homology-directed repair and breast cancer response to chemotherapy.

Chernikova SB, Nguyen RB, Truong JT, Mello SS, Stafford JH, Hay MP, Olson A, Solow-Cordero DE, Wood DJ, Henry S, von Eyben R, Deng L, Gephart MH, Aroumougame A, Wiese C, Game JC, Győrffy B, Brown JM.

J Clin Invest. 2018 Dec 3;128(12):5307-5321. doi: 10.1172/JCI87191. Epub 2018 Oct 29.

5.

Challenging the heterogeneity of disease presentation in malignant melanoma-impact on patient treatment.

Marcell Szasz A, Malm J, Rezeli M, Sugihara Y, Betancourt LH, Rivas D, Gyorffy B, Marko-Varga G.

Cell Biol Toxicol. 2018 Oct 24. doi: 10.1007/s10565-018-9446-9. [Epub ahead of print] Review.

PMID:
30357519
6.

A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy.

Gelfo V, Mazzeschi M, Grilli G, Lindzen M, Santi S, D'Uva G, Győrffy B, Ardizzoni A, Yarden Y, Lauriola M.

Cancers (Basel). 2018 Sep 26;10(10). pii: E355. doi: 10.3390/cancers10100355.

7.

The phosphatidic acid phosphatase lipin-1 facilitates inflammation-driven colon carcinogenesis.

Meana C, García-Rostán G, Peña L, Lordén G, Cubero Á, Orduña A, Győrffy B, Balsinde J, Balboa MA.

JCI Insight. 2018 Sep 20;3(18). pii: 97506. doi: 10.1172/jci.insight.97506. [Epub ahead of print]

8.

Factors influencing the scientific performance of Momentum grant holders: an evaluation of the first 117 research groups.

Győrffy B, Nagy AM, Herman P, Török Á.

Scientometrics. 2018;117(1):409-426. doi: 10.1007/s11192-018-2852-1. Epub 2018 Jul 20.

9.

Demographic shift disproportionately increases cancer burden in an aging nation: current and expected incidence and mortality in Hungary up to 2030.

Menyhárt O, Fekete JT, Győrffy B.

Clin Epidemiol. 2018 Aug 29;10:1093-1108. doi: 10.2147/CLEP.S155063. eCollection 2018.

10.

Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.

Pérez-Peña J, Győrffy B, Amir E, Pandiella A, Ocaña A.

Breast Cancer Res Treat. 2018 Sep 11. doi: 10.1007/s10549-018-4965-x. [Epub ahead of print]

PMID:
30206781
11.

Activation of Farnesoid X Receptor impairs the tumor-promoting function of breast cancer-associated fibroblasts.

Barone I, Vircillo V, Giordano C, Gelsomino L, Győrffy B, Tarallo R, Rinaldi A, Bruno G, Caruso A, Romeo F, Bonofiglio D, Andò S, Catalano S.

Cancer Lett. 2018 Nov 28;437:89-99. doi: 10.1016/j.canlet.2018.08.026. Epub 2018 Sep 1.

PMID:
30176263
12.

Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia.

Than NG, Romero R, Tarca AL, Kekesi KA, Xu Y, Xu Z, Juhasz K, Bhatti G, Leavitt RJ, Gelencser Z, Palhalmi J, Chung TH, Gyorffy BA, Orosz L, Demeter A, Szecsi A, Hunyadi-Gulyas E, Darula Z, Simor A, Eder K, Szabo S, Topping V, El-Azzamy H, LaJeunesse C, Balogh A, Szalai G, Land S, Torok O, Dong Z, Kovalszky I, Falus A, Meiri H, Draghici S, Hassan SS, Chaiworapongsa T, Krispin M, Knöfler M, Erez O, Burton GJ, Kim CJ, Juhasz G, Papp Z.

Front Immunol. 2018 Aug 8;9:1661. doi: 10.3389/fimmu.2018.01661. eCollection 2018.

13.

Tip110/SART3 regulates IL-8 expression and predicts the clinical outcomes in melanoma.

Timani KA, Győrffy B, Liu Y, Mohammad KS, He JJ.

Mol Cancer. 2018 Aug 17;17(1):124. doi: 10.1186/s12943-018-0868-z.

14.

Author Correction: Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets.

Nagy Á, Lánczky A, Menyhárt O, Győrffy B.

Sci Rep. 2018 Jul 26;8(1):11515. doi: 10.1038/s41598-018-29514-3.

15.

Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer.

Patten DK, Corleone G, Győrffy B, Perone Y, Slaven N, Barozzi I, Erdős E, Saiakhova A, Goddard K, Vingiani A, Shousha S, Pongor LS, Hadjiminas DJ, Schiavon G, Barry P, Palmieri C, Coombes RC, Scacheri P, Pruneri G, Magnani L.

Nat Med. 2018 Sep;24(9):1469-1480. doi: 10.1038/s41591-018-0091-x. Epub 2018 Jul 23.

PMID:
30038216
16.

[Genome engineering using the CRISPR-Cas9 system and applications in cancer research].

Hudacsek V, Gyõrffy B.

Magy Onkol. 2018 Jul 20;62(2):119-127. Epub 2018 Jan 6. Hungarian.

17.

[Longer oral contraception history as a possible preventive factor against fetal trisomy 21 in advanced maternal age pregnancies].

Horányi D, Babay LÉ, Győrffy B, Nagy GR.

Orv Hetil. 2018 Jul;159(28):1146-1152. doi: 10.1556/650.2018.31094. Hungarian.

PMID:
29983104
18.

Afatinib restrains K-RAS-driven lung tumorigenesis.

Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E.

Sci Transl Med. 2018 Jun 20;10(446). pii: eaao2301. doi: 10.1126/scitranslmed.aao2301.

PMID:
29925635
19.

Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets.

Nagy Á, Lánczky A, Menyhárt O, Győrffy B.

Sci Rep. 2018 Jun 15;8(1):9227. doi: 10.1038/s41598-018-27521-y. Erratum in: Sci Rep. 2018 Jul 26;8(1):11515.

20.

Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics.

Noack S, Raab M, Matthess Y, Sanhaji M, Krämer A, Győrffy B, Kaderali L, El-Balat A, Becker S, Strebhardt K.

Oncotarget. 2018 May 25;9(40):25842-25859. doi: 10.18632/oncotarget.25386. eCollection 2018 May 25.

21.

Local apoptotic-like mechanisms underlie complement-mediated synaptic pruning.

Györffy BA, Kun J, Török G, Bulyáki É, Borhegyi Z, Gulyássy P, Kis V, Szocsics P, Micsonai A, Matkó J, Drahos L, Juhász G, Kékesi KA, Kardos J.

Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6303-6308. doi: 10.1073/pnas.1722613115. Epub 2018 May 29.

22.

MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity.

Skucha A, Ebner J, Schmöllerl J, Roth M, Eder T, César-Razquin A, Stukalov A, Vittori S, Muhar M, Lu B, Aichinger M, Jude J, Müller AC, Győrffy B, Vakoc CR, Valent P, Bennett KL, Zuber J, Superti-Furga G, Grebien F.

Nat Commun. 2018 May 18;9(1):1983. doi: 10.1038/s41467-018-04329-y.

23.

Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.

West DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, Hosfield DJ, Lastra RR, Sinnwell JP, Thompson KJ, Bowie KR, Harkless RV, Skor MN, Pierce CF, Styke SC, Kim CR, de Wet L, Greene GL, Boughey JC, Goetz MP, Kalari KR, Wang L, Fleming GF, Györffy B, Conzen SD.

Clin Cancer Res. 2018 Jul 15;24(14):3433-3446. doi: 10.1158/1078-0432.CCR-17-2793. Epub 2018 Apr 10.

PMID:
29636357
24.

Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.

Martínez-Canales S, López de Rodas M, Nuncia-Cantarero M, Páez R, Amir E, Győrffy B, Pandiella A, Galán-Moya EM, Ocaña A.

Cancer Med. 2018 May;7(5):1896-1907. doi: 10.1002/cam4.1406. Epub 2018 Mar 25.

25.

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.

Győrffy B, Pongor L, Bottai G, Li X, Budczies J, Szabó A, Hatzis C, Pusztai L, Santarpia L.

Br J Cancer. 2018 Apr;118(8):1107-1114. doi: 10.1038/s41416-018-0030-0. Epub 2018 Mar 21.

PMID:
29559730
26.

Inhibin Is a Novel Paracrine Factor for Tumor Angiogenesis and Metastasis.

Singh P, Jenkins LM, Horst B, Alers V, Pradhan S, Kaur P, Srivastava T, Hempel N, Győrffy B, Broude EV, Lee NY, Mythreye K.

Cancer Res. 2018 Jun 1;78(11):2978-2989. doi: 10.1158/0008-5472.CAN-17-2316. Epub 2018 Mar 13.

PMID:
29535220
27.

Transcriptome evolution from breast epithelial cells to basal-like tumors.

Santpere G, Alcaráz-Sanabria A, Corrales-Sánchez V, Pandiella A, Győrffy B, Ocaña A.

Oncotarget. 2017 Dec 8;9(1):453-463. doi: 10.18632/oncotarget.23065. eCollection 2018 Jan 2.

28.

[Colorectal cancer heterogeneity: the clinical impact of sporadic lesions arising via the serrated pathway].

Ágoston EI, Horváth E, Győrffy B, Harsányi L, Szász AM.

Orv Hetil. 2018 Feb;159(6):206-214. doi: 10.1556/650.2018.30974. Review. Hungarian.

PMID:
29400100
29.

Erratum to "Effect of extended oral contraception use on the prevalence of fetal trisomy 21 in women aged at least 35 years": [Int J Gynecol Obstet 138(2017) 261-266].

Horányi D, Babay LÉ, Rigó J Jr, Győrffy B, Nagy GR.

Int J Gynaecol Obstet. 2018 Feb;140(2):258. doi: 10.1002/ijgo.12400. No abstract available.

PMID:
29313983
30.

A snapshot of 3649 Web-based services published between 1994 and 2017 shows a decrease in availability after 2 years.

Osz Á, Pongor LS, Szirmai D, Gyorffy B.

Brief Bioinform. 2017 Dec 8. doi: 10.1093/bib/bbx159. [Epub ahead of print]

PMID:
29228189
31.

Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.

Budczies J, Denkert C, Győrffy B, Schirmacher P, Stenzinger A.

BMC Med Genomics. 2017 Dec 6;10(1):74. doi: 10.1186/s12920-017-0308-8.

32.

CEACAM6 is a prognostic biomarker and potential therapeutic target for gastric carcinoma.

Ru GQ, Han Y, Wang W, Chen Y, Wang HJ, Xu WJ, Ma J, Ye M, Chen X, He XL, Győrffy B, Zhao ZS, Huang D.

Oncotarget. 2017 Jul 20;8(48):83673-83683. doi: 10.18632/oncotarget.19415. eCollection 2017 Oct 13.

33.

UCP2 and PRMT1 are key prognostic markers for lung carcinoma patients.

Madreiter-Sokolowski CT, Győrffy B, Klec C, Sokolowski AA, Rost R, Waldeck-Weiermair M, Malli R, Graier WF.

Oncotarget. 2017 Aug 28;8(46):80278-80285. doi: 10.18632/oncotarget.20571. eCollection 2017 Oct 6.

34.

DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer.

Menyhart O, Budczies J, Munkácsy G, Esteva FJ, Szabó A, Miquel TP, Győrffy B.

Oncotarget. 2017 Aug 24;8(44):77207-77218. doi: 10.18632/oncotarget.20430. eCollection 2017 Sep 29.

35.

Quantitative proteomics identifies STEAP4 as a critical regulator of mitochondrial dysfunction linking inflammation and colon cancer.

Xue X, Bredell BX, Anderson ER, Martin A, Mays C, Nagao-Kitamoto H, Huang S, Győrffy B, Greenson JK, Hardiman K, Spence JR, Kamada N, Shah YM.

Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):E9608-E9617. doi: 10.1073/pnas.1712946114. Epub 2017 Oct 23.

36.

PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer.

Xu H, Han Y, Lou J, Zhang H, Zhao Y, Győrffy B, Li R.

Oncotarget. 2017 May 13;8(41):69520-69526. doi: 10.18632/oncotarget.17846. eCollection 2017 Sep 19.

37.

Tumor-associated macrophages (TAMs) depend on ZEB1 for their cancer-promoting roles.

Cortés M, Sanchez-Moral L, de Barrios O, Fernández-Aceñero MJ, Martínez-Campanario MC, Esteve-Codina A, Darling DS, Győrffy B, Lawrence T, Dean DC, Postigo A.

EMBO J. 2017 Nov 15;36(22):3336-3355. doi: 10.15252/embj.201797345. Epub 2017 Oct 16.

38.

Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.

Stires H, Heckler MM, Fu X, Li Z, Grasso CS, Quist MJ, Lewis JA, Klimach U, Zwart A, Mahajan A, Győrffy B, Cavalli LR, Riggins RB.

Mol Cell Endocrinol. 2018 Aug 15;471:105-117. doi: 10.1016/j.mce.2017.09.024. Epub 2017 Sep 19.

39.

Alterations in SCAI Expression during Cell Plasticity, Fibrosis and Cancer.

Gasparics Á, Kökény G, Fintha A, Bencs R, Mózes MM, Ágoston EI, Buday A, Ivics Z, Hamar P, Győrffy B, Rosivall L, Sebe A.

Pathol Oncol Res. 2018 Jul;24(3):641-651. doi: 10.1007/s12253-017-0293-4. Epub 2017 Aug 16.

PMID:
28815470
40.

linc00673 (ERRLR01) is a prognostic indicator of overall survival in breast cancer.

Abdul-Rahman U, Győrffy B, Adams BD.

Transcription. 2018;9(1):17-29. doi: 10.1080/21541264.2017.1329684. Epub 2017 Oct 4.

41.

Cell Dispersal Influences Tumor Heterogeneity and Introduces a Bias in NGS Data Interpretation.

Pongor L, Harami-Papp H, Méhes E, Czirók A, Győrffy B.

Sci Rep. 2017 Aug 4;7(1):7358. doi: 10.1038/s41598-017-07487-z.

42.

Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.

Zhai L, Ladomersky E, Lauing KL, Wu M, Genet M, Gritsina G, Győrffy B, Brastianos PK, Binder DC, Sosman JA, Giles FJ, James CD, Horbinski C, Stupp R, Wainwright DA.

Clin Cancer Res. 2017 Nov 1;23(21):6650-6660. doi: 10.1158/1078-0432.CCR-17-0120. Epub 2017 Jul 27.

43.

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients.

Bottai G, Raschioni C, Székely B, Di Tommaso L, Szász AM, Losurdo A, Győrffy B, Ács B, Torrisi R, Karachaliou N, Tőkés T, Caruso M, Kulka J, Roncalli M, Santoro A, Mantovani A, Rosell R, Reis-Filho JS, Santarpia L.

NPJ Breast Cancer. 2016 Nov 2;2:16033. doi: 10.1038/npjbcancer.2016.33. eCollection 2016.

44.

ADIPOQ/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11/LKB1-mediated activation of the AMPK-ULK1 axis.

Chung SJ, Nagaraju GP, Nagalingam A, Muniraj N, Kuppusamy P, Walker A, Woo J, Győrffy B, Gabrielson E, Saxena NK, Sharma D.

Autophagy. 2017 Aug 3;13(8):1386-1403. doi: 10.1080/15548627.2017.1332565. Epub 2017 Jul 11.

45.

Effect of extended oral contraception use on the prevalence of fetal trisomy 21 in women aged at least 35 years.

Horányi D, Babay LÉ, Rigó J Jr, Győrffy B, Nagy GR.

Int J Gynaecol Obstet. 2017 Sep;138(3):261-266. doi: 10.1002/ijgo.12238. Epub 2017 Jul 5. Erratum in: Int J Gynaecol Obstet. 2018 Feb;140(2):258.

PMID:
28608970
46.

Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3.

Sengupta S, Nagalingam A, Muniraj N, Bonner MY, Mistriotis P, Afthinos A, Kuppusamy P, Lanoue D, Cho S, Korangath P, Shriver M, Begum A, Merino VF, Huang CY, Arbiser JL, Matsui W, Győrffy B, Konstantopoulos K, Sukumar S, Marignani PA, Saxena NK, Sharma D.

Oncogene. 2017 Oct 12;36(41):5709-5721. doi: 10.1038/onc.2017.164. Epub 2017 Jun 5.

47.

Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors.

Martínez-Canales S, Cifuentes F, López De Rodas Gregorio M, Serrano-Oviedo L, Galán-Moya EM, Amir E, Pandiella A, Győrffy B, Ocaña A.

PLoS One. 2017 May 4;12(5):e0175128. doi: 10.1371/journal.pone.0175128. eCollection 2017.

48.

Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer.

Safonov A, Jiang T, Bianchini G, Győrffy B, Karn T, Hatzis C, Pusztai L.

Cancer Res. 2017 Jun 15;77(12):3317-3324. doi: 10.1158/0008-5472.CAN-16-3478. Epub 2017 Apr 20.

49.

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors.

Pérez-Peña J, Alcaraz-Sanabria A, Nieto-Jiménez C, Páez R, Corrales-Sánchez V, Serrano-Oviedo L, Wali VB, Patwardhan GA, Amir E, Győrffy B, Pandiella A, Ocaña A.

Oncotarget. 2017 Mar 28;8(13):21733-21740. doi: 10.18632/oncotarget.15562.

50.

Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.

Iwamoto T, Katagiri T, Niikura N, Miyoshi Y, Kochi M, Nogami T, Shien T, Motoki T, Taira N, Omori M, Tokuda Y, Fujiwara T, Doihara H, Gyorffy B, Matsuoka J.

Oncotarget. 2017 Apr 18;8(16):26122-26128. doi: 10.18632/oncotarget.15385.

Supplemental Content

Loading ...
Support Center